PHARMA
PAREXEL Opens Office In Shenyang, China
PAREXEL International Corporation opened in May a new office in Shenyang, China to support client demand for clinical development capabilities in the region.
Merck & BeiGene To Co-Develop 2nd Gen BRAF Inhibitor
Merck Serono and BeiGene have agreed to co-develop a second-generation BRAF inhibitor for the treatment of cancer.
EBOS Group Limited Acquires Australian Pharma Distributor, Symbion
EBOS Group Limited announced this week details of a NZ$1.1 billion acquisition of Australia's Symbion.
ASLAN’s Pan-HER Inhibitor Shows Positive Data In Gastric Cancer PhII Study
ASLAN Pharma announced this week positive data with ASLAN001 in a gastric cancer Phase II study.
Japan Launches Public-Private Partnership To Fight Neglected Diseases
The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.
Amgen & Astellas Enter Into Japan Alliance
Amgen and Astellas Pharma Inc. today announced a strategic alliance to co-develop and co-commercialize new medicines in Japan.
Zensun Announces Ph II Results For Neucardin™ Heart Failure Drug
Zensun Sci & Tech, Ltd. announced Thursday positive results of four completed Phase II clinical trials for its anti-heart failure drug, Neucardin™.
Vectura & Partners Establish Kinnovata Pharma In China
UK-based Vectura Group plc has established Tianjin Kinnovata Pharmaceutical Company Limited in China with two partners.
RuiYi, Genor Biopharma To Collaborate On Anti-Inflammation Monoclonal Drug
RuiYi Inc. has entered into an exclusive license and collaborative agreement with Genor Biopharma for the development of RYI-008 in China.
